Results 281 to 290 of about 465,660 (315)

Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease

British Journal of Clinical Pharmacology, 2007
Thorsten Lehr
exaly  

Circ_0078767 suppresses non‐small‐cell lung cancer by protecting RASSF1A expression via sponging miR‐330‐3p

Cell Proliferation, 2019
Wenhui Li
exaly  

MiR‐330‐5p negatively regulates ovine preadipocyte differentiation by targeting branched‐chain aminotransferase 2

Animal Science Journal, 2018
Wenzhong Liu, Yangyang Pan, Tao Shi
exaly  

ABSTRACT 330

Pediatric Critical Care Medicine, 2014
L.G. Maxwell, G.M. Buckley, S.R. Kudchadkar, E. Ely, E. Stebbins, C. Dube, A. Morad, E.A. Jastaniah, N.F. Sethna, M. Yaster   +9 more
openaire   +1 more source

Antisecretory and antiulcer effect of T-330, a novel reversible proton pump inhibitor, in rats

European Journal of Pharmacology, 1997
Mine Kinoshita, Hajime Tamaki
exaly  

Case 330

2010
openaire   +2 more sources

§. 330

openaire   +1 more source

TSAA-330

Drugs of the Future, 1980
J. Castañer, K. Hillier
openaire   +1 more source

Downregulated microRNA‐330 suppresses left ventricular remodeling via the TGF‐β1/Smad3 signaling pathway by targeting SRY in mice with myocardial ischemia–reperfusion injury

Journal of Cellular Physiology, 2019
Jing-Jing Rong, Yan Cao, Yi Tang
exaly  

声 (330)

1905
openaire   +1 more source